Table 1 Basic characteristics
Characteristic | Study Group (n = 174) | Control Group (n = 175) | P-value | |
|---|---|---|---|---|
Demographics | ||||
Mean age (years) | 47.3 ± 11.9 | 46.5 ± 10.9 | 0.491 | |
Age (subgroups): | 0.770 | |||
18–41 y.o. | 60 (34.5%) | 66 (37.7%) | ||
42–51 y.o. | 60 (34.5%) | 54 (30.9%) | ||
≥ 52 y.o. | 54 (31%) | 55 (31.4%) | ||
Gender - Male | 91 (52.3%) | 105 (60.0%) | 0.132 | |
Origin -African descendant | 122 (70.1%) | 117 (66.9%) | 0.490 | |
HIV Parameters at diagnosis | ||||
Viral load (copies/ml) | 323,622 ± 702,463 | 837,396 ± 5,915,115 | 0.313 | |
CD4 (cells/μl) | 239 ± 178 | 272 ± 234 | 0.187 | |
Nadir CD4 (cells/μl) | 147 ± 94 | 159 ± 125 | 0.358 | |
Weight (kg) | 60.4 ± 10.5 | 63.4 ± 13.2 | 0.071 | |
BMI (kg/m2) | 21.9 ± 3.2 | 22.9 ± 3.9 | 0.045 | |
Time between HIV diagnosis and ART initiation (years) | 2.4 ± 3.08 | 1.86 ± 3.03 | 0.175 | |
Time between diagnosis and time 0 (years) | 10.48 ± 5.4 | 7.86 ± 4.38 | < 0.001 | |
Treatment duration before time 0 (years) | 8.03 ± 4.79 | 6.10 ± 3.86 | < 0.001 | |
Viral suppression duration before time 0 | 70.0 ± 50.9 | 56.0 ± 4.3 | 0.0028 | |
Parameters at time 0 | ||||
Viral load (copies/ml) | 9539 ± 80,479 | 503 ± 6292 | 0.14 | |
Patients with viral load ≤50 | 166 (95.4%) | 162 (92.6%) | 0.26 | |
CD4 (cells/μl) | 533 ± 248 | 518 ± 258 | 0.59 | |
Weight (kg) | 66.7 ± 12 | 68.7 ± 13.0 | 0.136 | |
BMI (kg/m2) | 24.4 ± 3.7 | 24.8 ± 3.9 | 0.3 | |
Mean blood pressure (mmHg) | 88 ± 10 | 90 ± 10 | 0.2 | |
Total cholesterol (mg/dL) | 187 ± 43 | 190 ± 43 | 0.44 | |
LDL (mg/dL) | 113 ± 44 | 115 ± 34 | 0.8 | |
HDL (mg/dL) | 47 ± 14 | 48.3 ± 13.5 | 0.4 | |
Triglycerides (mg/dL) | 154 ± 96 | 155 ± 143 | 0.939 | |
Glucose (mg/dL) | 97.7 ± 28.2 | 97.1 ± 28.0 | 0.836 | |
ART | Pre-switch | Post-switch | ||
Core agent | ||||
NNRTI | 53 | – | 115 | |
PI | 121 | – | 60 | |
INSTI type | ||||
Dolutegravir | – | 84 | – | |
Elvitegravir/Cobicistat | – | 49 | – | |
Raltegravir | – | 41 | – | |
Backbone agent | ||||
TDF/FTC (Truvada) | 136 | 94 | 159 | |
TAF/FTC | – | 48 | – | |
ABC/3TC (Kivexa) | 32 | 53 | 14 | |
AZT/3TC (Combivir) | 32 | 5 | 27 | |